Cite
HARVARD Citation
Liu, Z. et al. (2018). Does ALK‐rearrangement predict favorable response to the therapy of bevacizumab plus pemetrexed in advanced non‐small‐cell lung cancer? Case report and literature review. Clinical and translational medicine. 7 (1), p. n/a. [Online].